← Eichor
Study identifier: NCT06463392 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Deep Learning-based sbORN Diagnostic Model

Condition: Nasopharyngeal Carcinoma · Herpesvirus 4, Human  ·  Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

PhaseN/A
Planned participants312
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Skull-base osteonecrosis (sbORN) is a severe long-term complication of nasopharyngeal carcinoma (NPC) post radiotherapy, which significantly diminish the quality of life, increase the risk of internal carotid artery rupture, and is frequently misdiagnosed as NPC recurrence. Novel diagnostic tools are therefore clinically significant. In this study, the investigators seek to ask if a deep-learning-based model shows a significantly higher sensitivity than radiologists. With a cross-sectional design, the investigators aim to recruit 312 participants in Sun Yat-sen Memorial Hospital, Guangzhou, China that meet the eligibility criteria.

This description comes directly from the study's public registry record.

Talk to the study team

Xiang-Wei Kong, Ph.D.  ·  0086-020-34071439  ·  kongxw8@mail.sysu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06463392